Popular terms

Expression Vector topics
Expression Vector
Recombinant
Nucleic Acid
Antibodies
Polypeptide
Amino Acid
Amino Acid Sequence
Nucleic Acids
Polynucleotide
Nucleotide
Cytomegalovirus
Endothelial
Extracellular
Endothelial Cell
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Expression Vector patents



      

This page is updated frequently with new Expression Vector-related patent applications.




Date/App# patent app List of recent Expression Vector-related patents
04/14/16
20160102136 
 Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use patent thumbnailSingle-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
Isolated vhh monoclonal antibodies are disclosed that specifically bind to a norovirus polypeptide. In some embodiments, the norovirus is a genogroup i norovirus or a genogroup ii norovirus.

04/14/16
20160102133 
 Mutant factor viii compositions and methods patent thumbnailMutant factor viii compositions and methods
In one aspect, present invention provides a recombinant mutant human factor viii having increased expression and/or secretion as compared to wild-type factor viii. In certain embodiments, the recombinant factor viii includes one or more amino acid substitution(s) selected from the group consisting of i86, y105, a108, d115, q117, f129, g132, h134, m147 and l152.

04/14/16
20160102128 
 Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells patent thumbnailCodon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/14/16
20160102125 
 Expression systems and associated methods patent thumbnailExpression systems and associated methods
A method of producing synthetic spider silk, including: transforming escherichia coli with an expression vector; fermenting the transformed e. Coli in a culture medium; inducing spider silk protein expression in the cultured e.

04/07/16
20160097053 
 Yeast promoters from pichia pastoris patent thumbnailYeast promoters from pichia pastoris
In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


04/07/16
20160096875 
 Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells patent thumbnailCodon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160095919 
 Therapeutic agent for neurological disorder patent thumbnailTherapeutic agent for neurological disorder
Provided is a therapeutic agent for a neurological disorder directly acting on oxygen concentration-dependent vascular barrier breakdown. The therapeutic agent for a neurological disorder contains any one of (a) a functional nucleic acid against adam (a disintegrin and metalloproteinase)12 or adam17, (b) a functional nucleic acid expression vector containing a dna encoding the functional nucleic acid (a) and (c) a neutralizing antibody against adam12 or adam17, as an active ingredient.
Yamaguchi University


03/31/16
20160089432 
 Methods and compositions for inducing protective immunity against human immunodeficiency virus infection patent thumbnailMethods and compositions for inducing protective immunity against human immunodeficiency virus infection
Compositions, vaccines and methods for inducing protective immunity against human immunodeficiency virus (hiv) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of hiv..
Crucell Holland B.v.


03/17/16
20160076051 
 Expression process patent thumbnailExpression process
A process for the production of a target polypeptide is provided. The process comprises expression of an expression vector for expressing a target polypeptide in a host cell, preferably a mammalian cell, the expression vector comprising an expression cassette comprising a polynucleotide encoding a recombinant polypeptide operably linked to a fibronectin secretion leader sequence; and recovering the target polypeptide..
Fujifilm Diosynth Biotechnologies Uk Limited


03/17/16
20160075797 
 Anti-vasa antibodies, and methods of production and use thereof patent thumbnailAnti-vasa antibodies, and methods of production and use thereof
Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.


03/17/16
20160075782 

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)


The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.


03/10/16
20160068856 

Fungal resistant plants expressing mybtf


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales in plants and/or plant cells. This is achieved by increasing the expression of a mybtf protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


03/10/16
20160068849 

Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy


Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell.
Alderbio Holdings Llc


03/03/16
20160060639 

Positive-selection cloning and expression vector based on the toxicity of killin


Here we report the creation of a new positive-selection cloning vector dubbed pkillin, which overcomes all of the above pitfalls. The essence behind its high cloning efficiency is the extreme toxicity and small size of the toxic domain of killin, a recently discovered p53 target gene.

03/03/16
20160060354 

Site-specific glycoengineering of targeting moieties


The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


03/03/16
20160058852 

Immunotherapy of cancer through combination of local and systemic immune stimulation


Provided herein are compositions and methods for immunotherapy of cancers, said methods combining systemic vaccination with a recombinant expression vector encoding a viral antigen and/or a cancer specific tumor antigen(s) to induce activated cd8 t-cells, with a local (e.g., intratumoral) immune stimulation using standard or modified application of a tlr agonist, to induce local inflammatory and innate immune responses which recruit t-cells to the tumor.. .
Immune Design Corp.


02/25/16
20160053017 

Anti-cd276 polypeptides, proteins, and chimeric antigen receptors


Polypeptides and proteins that specifically bind to and immunologically recognize cd276 are disclosed. Chimeric antigen receptors (cars), anti-cd276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed.
Biomed Valley Discoveries, Inc.


02/25/16
20160051658 

Neisserial antigenic peptides


This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria neisseria meningitidis b. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids).
Glaxosmithkline Biologicals Sa


02/18/16
20160046957 

Production of fully processed and functional factor x in a furin-secreting mammalian expression system


Disclosed herein are methods for production of fully-processed mature factor x in an expression system producing a controlled amount of furin between 50 u/ml and 300 u/ml of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and factor x..
Baxalta Gmbh


02/18/16
20160046921 

Enzymatic methods and enzymes


Provided are methods to identify modulators and in particular inhibitors of body malodour formation employing peptidase enzymes, the peptidase enzymes and corresponding nucleotide sequences, expression vectors, transfected host cells, methods of forming the peptidase enzymes and methods to prevent body malodour.. .
Givaudan Sa


02/18/16
20160046701 

Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy


The present invention is based, in part, on our discovery that targeting epitopes within one or more of the ec2-ec5 subdomains of e-cadherin results in the death of epithelial-derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include polypeptides having an amino acid sequence of one or more of the ec2-ec5 subdomains of e-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the ec2-ec5 subdomains.
The Research Foundation For The State University Of New York


02/18/16
20160046694 

Methods and constructs for expressing biologically active proteins in mammalian cells


Methods and constructs for expressing biologically active proteins in eukaryotic cells are disclosed. A method for producing a non-conventional expression vector for production of biologically active compounds comprising a primary transcriptional unit and one or more secondary transcriptional units, a primary transcriptional unit encoding promoter, synthetic intron, selectable marker gene and polyadenylation signal or transcriptional terminator and a second transcriptional unit encoding promoter and polypeptide of interest surrounded by insulator sequences and placed in the intron of primary transcriptional unit.
Usha Biotech Limited


02/18/16
20160046691 

Novel epitope for switching to th2 cell and use thereof


The present invention relates to a novel epitope to convert t cell to type 2 helper t (th2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody..

02/18/16
20160046677 

Pseudomonas exotoxin a with less immunogenic b cell epitopes


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more of amino acid residues e420, d463, y481, l516, r563, d581, d589, and k606, wherein the amino acid residues are defined by reference to seq id no: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


02/11/16
20160040185 

Expression vector and preparing a polypeptide of interest using the same


A fusion polynucleotide including a human cmv promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell comprising the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector or recombinant cell.. .
Samsung Electronics Co., Ltd.


02/11/16
20160040184 

Phi-4 polypeptides and methods for their use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred International, Inc.


02/11/16
20160040182 

Fungal resistant plants expressing hcp5


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an hcp5 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


02/11/16
20160040173 

Light-switchable gene expression system and the methods for controlling gene expression in prokaryotic bacterium


Provided is an optically controlled gene expression system of prokaryotic bacterium, comprising: a) a photosensitive recombinant transcription factor encoding gene, the photosensitive recombinant transcription factor is one fusion protein comprising a first polypeptide as the dna bonding domain and a second polypeptide as the photosensitive domain; b) a target transcription unit comprising promoter or promoter-reaction element or reaction element-promoter containing at least one reaction element recognized/bound by the first polypeptide and the nucleic acid sequence to be transcribed. Also provided is a prokaryotic expression vector comprising said optically controlled gene expression system, and a method for regulating gene expression in a prokaryotic host cell by using the optically controlled gene expression system.
East China University Of Science And Technology


02/11/16
20160040157 

Multi-chain eukaryotic display vectors and uses thereof


A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin fab fragments.
Dyax Corp.


02/11/16
20160039933 

Antibodies specific to cadherin-17


The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to cadherin-17 with high affinity. Nucleic acid molecules encoding cadherin-17 antibodies, expression vectors, host cells and methods for expressing the cadherin-17 antibodies are also provided.
Oxford Biotherapeutics Limited


02/11/16
20160039908 

Method and pharmaceutical composition for use in the treatment of cancer


The present invention relates to a soluble peptide comprising the amino acids sequence: krfyvvmwkk (seq id no: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier..
Assistance Publique-hopitaux De Paris


02/11/16
20160038578 

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof


Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind hmw-maa. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


02/11/16
20160038576 

Immunogenic compositions for inducing an immune response for elimination of senescent cells


Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof..
Buck Institute For Research On Aging


02/04/16
20160032283 

Random rnai libraries, methods of generating same, and screening methods utilizing same


This invention provides expression vectors for a ribonucleic acid (rna) molecule comprising a double-stranded region of random sequence, sets and libraries of same, methods of generating same, and methods for identifying an rna therapeutic or rna molecule that has an ability to affect a biological parameter, for identifying a drug target for a disease or disorder of interest, and for identifying a variant of an rna molecule that has an altered ability to affect a biological parameter of interest.. .
The Trustees Of The University Of Pennsylvania


02/04/16
20160032279 

Polypeptide display libraries and methods of making and using thereof


Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand.
The Regents Of The University Of California


02/04/16
20160032256 

Cytochrome p450s and uses thereof


The invention features isolated cytochrome p450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds..
University Of Kentucky Research Foundation


02/04/16
20160031949 

Novel insecticidal proteins and methods of use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred International, Inc.


02/04/16
20160030597 

S100b mini-promoters


Isolated polynucleotides comprising a s100b mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia


01/28/16
20160024600 

Coincidence reporter gene system


Disclosed is a nucleic acid comprising a nucleotide sequence encoding (i) two or more reporters comprising a first reporter and a second reporter that is different from the first reporter; and (ii) one or more ribosomal skip sequences, wherein a ribosomal skip sequence is positioned between the first and second reporters, wherein the first and second reporters are stoichiometrically co-expressed from the nucleotide sequence and the nucleic acid does not comprise a cytomegalovirus-immediate early (cmv-ie) promoter. Also disclosed are methods of screening test compounds for ability to modulate a biological activity of interest using the nucleic acid, as well as related recombinant expression vectors, host cells, and populations of cells..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser


01/28/16
20160024530 

Cytochrome p450s and uses thereof


The invention features isolated cytochrome p450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds..
University Of Kentucky Research Foundation


01/28/16
20160024511 

Yeast promoters for protein expression


Isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are disclosed. More specifically, nucleic acids isolated from pichia pastoris having promoter activity and expression methods, host cells, expression vectors, and dna constructs of using the pichia pastoris promoters to produce different proteins and polypeptides are disclosed..
Biogrammatics, Inc.


01/28/16
20160024509 

Expression vector


An expression vector for expressing a target polypeptide in a prokaryotic cell is provided. The vector comprises a promoter operably linked to a polynucleotide encoding the target polypeptide operably linked to a eukaryotic secretion leader sequence, the eukaryotic secretion leader sequence encoding a signal peptide sequence selected from the group consisting of: a) mlkrsswlatlglltvasvstivya; b) mkkatfitcllavllvsnpiwna; c) mkvsaaalaviliatalcapasa; d) mkvstaflcllltvsafsaqvla; and e) mkclllalglalacaaqa.
Fujifilm Diosynth Biotechnologies Uk Limited


01/28/16
20160024221 

Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies


The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to fucosyl-gm1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.


01/28/16
20160024177 

Novel epitope for switching to th1 cell and use thereof


The present invention relates to a novel epitope that converts t cell to type 1 helper t (th1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th1 cell and a method for converting t cell to th1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody..

01/28/16
20160024174 

Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen


Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a ny-eso-1 antigen. Included are recombinant t cell receptors (tcrs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including cd4+ t cells, cd8+ t cells, natural killer t cells, γδ t cells, and progenitor cells, such as haematopoietic stem cells.
Health Research, Inc.


01/28/16
20160024159 

Potent and selective inhibitors of nav1.7


Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of nav1.7.
Amgen Inc.


01/28/16
20160022807 

Methods and compositions for in vivo immune stimulation and antigen production


Disclosed are compositions and methods comprising a vector and a reverse genetics competent unit. The vector may comprise baculovirus expression vectors, bacmids, vaccinia virus and synthetic vectors and the reverse genetics competent unit may comprise pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector.
University Of Maryland


01/21/16
20160017297 

Recombinant manganese oxidase


Disclosed herein is a recombinant bacillus manganese oxidase complex, including a bacterial expression vector for the expression of the complex and a method of synthesizing the complex.. .
Oregon Health & Science University


01/21/16
20160017289 

Tgif2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof


Disclosed are genetically modified human pancreatic progenitor cells, comprising an exogenous nucleic acid molecule encoding tgif2, for use as a medicament in the treatment of a subject with diabetes, in addition to methods for the production of said cells. Also disclosed is an expression vector encoding tgif2 for use as a medicament in the treatment of a subject with diabetes..
Max-delbrueck-centrum Fuer Molekulare Medizin


01/21/16
20160017281 

Cell expression system


An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (dhfr) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal sv 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the dhfr deficiency in the host cell; a prokaryotic selectable marker conveying ampicillin resistance to a prokaryotic host cell; a prokaryotic origin of replication; a plurality of multiple cloning sites (mcs); and at least one protein expression module comprising: a simian vacuolating virus 40 (sv40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a sv40 p a sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.. .
Neuclone Biologies Pty Ltd


01/21/16
20160017277 

Cell culture media composition and methods of producing thereof


A serum free cell culture media, wherein the media is adapted to be conditioned by culturing a first set of eukaryotic cells in the media, wherein the first set of eukaryotic cells use an expression vector to excrete levels of desired complex proteins into the media; wherein said desired complex proteins include human growth hormone (hgh), growth hormone-like growth factors, insulin-like growth factors, insulin, modified insulins, cytokines, mitogenic proteases and mixtures thereof; and wherein the media is adapted to grow a set of eukaryotic cells.. .
Neuclone Biologics Pty Ltd


01/21/16
20160017017 

Growth hormone compounds


The invention relates to growth hormone compounds with a long plasma half-life obtained by fc linkage. An increased half-life is an advantage allowing a less frequent or low dosage administration of therapeutic.
Novo Nordisk Healthcare Ag


01/21/16
20160017012 

Delivery of card protein as therapy for occular inflammation


The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating card to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization..
University Of Florida Research Foundation, Inc.


01/21/16
20160015062 

Feline bitter taste receptors and methods


A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors.
Applied Food Biotechnology, Inc.


01/21/16
20160015010 

Animal model of charcot-marie-tooth disease as hsp27 mutant (s135f) carrier


The present invention relates to a hsp27 mutation (s135f) mediated charcot-marie-tooth disease (cmt) animal model. Particularly, the vector expressing mutant hsp27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected.
Samsung Life Public Welfare Foundation


01/14/16
20160009788 

Monoclonal antibodies that neutralize a norovirus


Monoclonal neutralizing antibodies are disclosed that specifically bind to a norovirus. In some embodiments, the norovirus is a genogroup ii norovirus or a genogroup ii norovirus.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


01/14/16
20160009779 

Novel fusion tags and expression vector system for the expression of human parathyroid hormone (rhpth)


The present invention provides for fusion tags of 20 to 50 amino acids having a sequence as given in fig. 1, fusion tags sharing homology with these fusion tags, or hybrid fusion tags comprising sequences of fig.
Alkem Laboratories Ltd.


01/07/16
20160003852 

Feline bitter taste receptors and methods


A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors.
Applied Food Biotechnology, Inc.


01/07/16
20160002682 

In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes


The present invention provides methods for catalyzing the conversion of an olefin to any compound containing one or more cyclopropane functional groups using heme enzymes. In certain aspects, the present invention provides a method for producing a cyclopropanation product comprising providing an olefinic substrate, a diazo reagent, and a heme enzyme; and admixing the components in a reaction for a time sufficient to produce a cyclopropanation product.
California Institute Of Technology


01/07/16
20160002668 

Compositions and methods of use thereof for identifying anti-viral agents


The present disclosure provides a recombinant expression vector comprising a nucleotide sequence encoding a herpesvirus transactivator, where the nucleotide sequence is operably linked to a herpesvirus control element. The present disclosure provides cell lines genetically modified to express a herpesvirus transactivator under the control of a herpesvirus control element.
The J. David Gladstone Institutes


01/07/16
20160002666 

Methods and compositions for treating genetically linked diseases of the eye


Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.. .
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160000932 

Modified fc molecules


Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids).
Amgen Inc.


12/31/15
20150376632 

Promoters and methods thereof


A promoter, which may be used to transform a plant and/or express a gene substantially uniformly in substantially all organs and/or tissues of a plant, and which may include a constitutive expression promoter for transforming a monocot plant. A vector including a promoter, which may include a recombinant plant expression vector.
Seoul National University R&db Foundation


12/24/15
20150368661 

Methods for producing antibodies


Methods for producing antibodies are provided and include transforming a plant cell with a nucleic acid encoding a heavy chain of an antibody, a light chain of an antibody, and a linking polypeptide connecting the heavy chain to the light chain. The nucleic acid is then expressed in the plant cell, such that, upon expression the linking polypeptide is cleaved to separate the heavy chain from the light chain.
University Of Louisville Research Foundation, Inc.


12/24/15
20150368631 

Enzymes that cleave non-glycosidic ether bonds between lignins or derivatives thereof and saccharides


The patent application relates to isolated polypeptides that specifically cleave non-glycosidic ether bonds between lignins or derivatives thereof and saccharides, and to cdnas encoding the polypeptides. The patent application also relates to nucleic acid constructs, expression vectors and host cells comprising the cdnas, as well as methods of producing and using the isolated polypeptides for treating pulp and biomass to increase soluble saccharide yield and enrich lignin fractions..
Tethys Research Llc


12/24/15
20150368340 

Human monoclonal antibodies specific for glypican-3 and use thereof


Described herein is the identification of human monoclonal antibodies that bind gpc3 or heparan sulfate (hs) chains on gpc3 with high affinity. The antibodies described herein are capable of inhibiting hcc cell growth and migration.

12/17/15
20150361470 

Nonribosomal peptide synthetases


The present disclosure is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (nrps)-derived drug and analogs thereof. The invention provides polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the nrps-derived drug, the polypeptides encoded by such polynucleotides, expression vectors comprising the polynucleotides, host cells comprising the polynucleotides or expression vectors, and kits comprising a host cell.
Regents Of The University Of Michigan


12/17/15
20150361443 

Fungal resistant plants expressing hcp6


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacosporaceae in plants and/or plant cells. This is achieved by increasing the expression of an hcp6 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


12/17/15
20150361437 

Recombinant yeast transformant and process for preparing immunoglobulin fc fragment employing the same


The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin fc fragment into pichia sp. Yeast, a method for producing an immunoglobulin fc fragment comprising culturing the transformant, and recovering the immunoglobulin fc fragment from the culture, and an immunoglobulin fc fragment, prepared by the above method for use as a drug carrier.
Hanmi Pharm. Co., Ltd.


12/17/15
20150359878 

Use of replication deficient hsv-1 as a vaccine vector for the deli vary of hiv-1 tat antigen


A vaccine for a dna virus, especially hsv1, comprises an expression vector for hiv1 tat, wherein the vector is an avirulent form of said dna virus, and elicits cellular responses to cryptic epitopes of the dna virus, as well as eliciting a detectable igg response.. .
Vaxxit Srl


12/10/15
20150355184 

Antibodies that bind to human programmed death ligand 1 (pd-l1)


The present disclosure provides isolated antibodies that specifically bind to human pd-l1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-pd-l1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human pd-l1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human pd-l1 expression in tissue samples.
Merck Sharp & Dohme Corp.


12/10/15
20150353957 

Fungal resistant plants expressing hcp7


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacosporaceae in plants and/or plant cells. This is achieved by increasing the expression of an hcp7 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


12/10/15
20150353956 

Fungal resistant plants expressing ein2


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacopsoraceae in plants and/or plant cells. This is achieved by increasing the expression of an ein2 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


12/10/15
20150353940 

Vectors for use in an inducible coexpression system


The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product.. .
Absci, Llc


12/10/15
20150353938 

Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)


This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cdna encoding the rpgr protein.
Applied Genetic Technologies Corporation


12/10/15
20150353638 

Humanized monoclonal antibodies against the extracellular domain of human death receptor 5


The present invention provides a humanized monoclonal antibody against extracellular domain of human death receptor 5, comprising a light chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as seq id no: 1, a heavy chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as seq id no: 2, and constant region derived from human antibody. The present invention also provides nucleotide sequence encoding said humanized monoclonal antibody, a recombinant eukaryotic expression vector, a process for preparing the humanized monoclonal antibody, and the composition and use therefore.
Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences


12/03/15
20150344896 

System for expression of genes in plants from a virus-based expression vector


Modified expression vectors, including tobacco mosaic virus (tmv) expression vectors, methods for modifying such vectors, and uses of the same are disclosed.. .
The Ohio State University Research Foundation


12/03/15
20150344571 

Antibody binding specifically to human and mouse l1cam protein, and use therefor


The present invention relates to a novel antibody specifically binding to human and mouse l1cam, and more particularly, to an antibody binding to both human and mouse l1cam with high affinity, which is prepared by modifying a sequence of an l1 cell adhesion molecule (l1cam)-specific antibody comprising a heavy-chain variable region of seq id no. 1 and a light-chain variable region of seq id no.
Korea Research Institute Of Bioscience And Biotechnology


12/03/15
20150343020 

Tnnt1 mini-promoters


Isolated polynucleotides comprising a tnnt1 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia


11/26/15
20150337331 

Novel expression vector


Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector is an expression vector for expression of a mammalian protein and includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof, and a dihydrofolate reductase gene downstream of either the same gene expression regulatory site or another gene expression regulatory site in addition to the former..
Jcr Pharmaceuticals Co., Ltd.


11/26/15
20150337051 

Tem-1 diagnostic antibodies


Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (tem-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits.
Morphotek, Inc.


11/26/15
20150337038 

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)


The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons L. L. C.


11/12/15
20150322131 

Production of therapeutic proteins in genetically modified mammalian cells


The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as igf-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a.
Novartis Ag


11/05/15
20150315611 

Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells


Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (hsc) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increase a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers.
Children's Hospital Medical Center


11/05/15
20150315609 

Slc6a4 mini-promoters


Isolated polynucleotides comprising a slc6a4 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia


11/05/15
20150315608 

Mitochondrial expression vector and the transformation of mitochondria


The invention relates to a mitochondrial expression vector which may comprise a gene to be expressed and/or a selection marker and a mitochondrial region, and a method for inserting a dna to be expressed into mitochondria of mammalian cells, wherein the method may comprise the steps: (i) construction of a mitochondrial expression vector or a mitochondrial genome, (ii) reversible induction of megamitochondria and (iii) transfection of the megamitochondria by means of a physical transfection method.. .
Universitat Leipzig


11/05/15
20150315603 

Tobacco specific nitrosamine reduction in plants


In one aspect, there is provided a mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a member of the clc family of chloride channels and having at least 60% sequence identity to seq id no:1 or seq id no:2 or seq id no:3 or seq id no:4 or seq id no:10 or seq id no:11; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence encoding a member of the clc family of chloride channels and having at least 60% sequence identity to seq id no:5 or seq id no:6 or seq id no:7 or seq id no:12 or seq id no:13 or seq id no:14; or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i); and wherein the expression or activity of the polynucleotide or the polypeptide is modulated as compared to a control plant and wherein the nitrate levels in the mutant, non-naturally occurring or transgenic plant containing the mutant, non-naturally occurring or transgenic plant cell are modulated as compared to the control plant containing the control plant cell.. .
Philip Morris Products S.a.


11/05/15
20150315277 

Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including same


The present invention relates to a novel form of a dual-target antibody targeting vegfr-2 and dll4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.. .
Pharmabcine Inc.


10/29/15
20150307609 

Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof


The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i.e., thermal and chemical) stability.
Bristol-myers Squibb Company


10/29/15
20150307582 

Engineered receptors and their use


Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed.
University Of Pittsburgh-of The Commonwealth System Of Higher Education


10/22/15
20150299733 

Mutant beta-glucosidases having enhanced activity and a producing bioethanol using the same


The present invention relates to beta-glucosidase that is mutated to have enhanced activity, and a method for producing bioethanol using the same. More particularly, the present invention relates to a polynucleotide encoding beta-glucosidase that is mutated to have enhanced activity, beta-glucosidase expressed from the polynucleotide, an expression vector including the polynucleotide, a transformant that is transformed with the expression vector, a method for producing the mutated beta-glucosidase using the transformant, and a method for producing bioethanol using the transformant.
Korea Research Institute Of Bioscience And Biotechnology


10/22/15
20150299726 

Ahas mutants


The invention provides nucleic acids encoding mutants of the acetohydroxyacid synthase (ahas) large subunit comprising at least two mutations, for example double and triple mutants, which are useful for producing transgenic or non-transgenic plants with improved levels of tolerance to ahas-inhibiting herbicides. The invention also provides expression vectors, cells, plants comprising the polynucleotides encoding the ahas large subunit double and triple mutants, plants comprising two or more ahas large subunit single mutant polypeptides, and methods for making and using the same..
Basf Plant Science Gmbh


10/22/15
20150299721 

Biomass production increasing gene and transgenic plant using same


The present invention relates to, inter alia, a gene which increases biomass production isolated from arabidopsis thaliana, and a method for producing a transgenic plant by using same. More specifically, the present invention provides, inter alia, a composition, a recombinant expression vector and a transgenic plant for increasing plant biomass production, comprising a base sequence coding for the amino acid sequence of sequence number 2.
Postech Academy-industry Foundation


10/22/15
20150299707 

Construction of pool of interfering nucleic acids covering entire rna target sequence and related compositions


The present invention provides a pcr based high-throughput method for preparing full-sites sirna polynucleotide pool, comprising: dnase i random digestion; loop-1 phosphate linker ligation; single pcr amplification; a type iii restriction/modification enzyme digestion; blunt ending; loop-2 phosphate linker ligation; double primer pcr; foki digestion and cloning into an sirna expression vector. The present invention enables the use of a type iii restriction/modification enzyme linkers mediated pcr method for high-throughput preparing an sirina polynucleotide pool, in which the functional length of sirnas can be controllably distributed from 19-23 bp, thus completely mimic the natural sirna length diversity, specially suitable for rnai therapeutic targets screening.
Biomics Biotechnologies Co., Ltd.


10/22/15
20150299683 

Egvii endoglucanase and nucleic acids encoding the same


The present invention provides a novel endoglucanase nucleic acid sequence, designated egl7, and the corresponding egvii amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding egvii, recombinant egvii proteins and methods for producing the same..
Danisco Us Inc.


10/22/15
20150299335 

Bi-specific antigen-binding polypeptides


The present invention provides antigen-binding polypeptides (e.g., bi-specific antigen-binding polypeptides) that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to her2 and antagonize her2 activation.
X-body, Inc.


10/22/15
20150299317 

M971 chimeric antigen receptors


The invention provides a chimeric antigen receptor (car) comprising an antigen binding domain comprising seq id nos: 1-6, a transmembrane domain, and an intracellular t cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America,as Represented By The Secretary, Department Of Health And Human Service


10/22/15
20150299276 

Alpha-conotoxin peptide, pharmaceutical composition and use thereof


The present invention provides a novel α-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide.
Hainan University




Expression Vector topics: Expression Vector, Recombinant, Nucleic Acid, Antibodies, Polypeptide, Amino Acid, Amino Acid Sequence, Nucleic Acids, Polynucleotide, Nucleotide, Cytomegalovirus, Endothelial, Extracellular, Endothelial Cell, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.6951

5530

3 - 0 - 101